Bryan Lemon
Amgen
21 Papers
168 Citations
Bryan Lemon is an academic researcher from Amgen. The author has contributed to research in topics: Receptor & FGF21. The author has an hindex of 15, co-authored 21 publications.
Chat about Author
Papers
C-terminal Tail of FGF19 Determines Its Specificity toward Klotho Co-receptors
Xinle Wu,Bryan Lemon,Xiaofan Li,Jamila Gupte,Jennifer Weiszmann,Jennitte Stevens,Nessa Hawkins,Wenyan Shen,Richard A. Lindberg,Jin-Long Chen,Hui Tian,Yang Li +11 more
TL;DR: The C-terminal tail of FGF19 is identified as a region necessary for its recognition of Klotho family proteins, providing the first glimpse of the regions that regulate the binding specificity between this unique family of F GFs and their co-receptors.
150
Characterization of a FGF19 Variant with Altered Receptor Specificity Revealed a Central Role for FGFR1c in the Regulation of Glucose Metabolism
Hongfei Ge,Helene Baribault,Steven Vonderfecht,Bryan Lemon,Jennifer Weiszmann,Jonitha Gardner,Ki Jeong Lee,Jamila Gupte,Paramita Mookherjee,Minghan Wang,Jackie Sheng,Xinle Wu,Yang Li +12 more
TL;DR: The results are the first direct demonstration of the central role of the βKlotho/FGFR1c receptor complex in glucose and lipid regulation, and strongly suggest that activation of this receptor complex alone might be sufficient to achieve all the metabolic functions of endocrine FGF molecules.
Dual actions of fibroblast growth factor 19 on lipid metabolism.
Xinle Wu,Hongfei Ge,Helene Baribault,Jamila Gupte,Jennifer Weiszmann,Bryan Lemon,Jonitha Gardner,Preston Fordstrom,Jie Tang,Mingyue Zhou,Minghan Wang,Yang Li +11 more
TL;DR: It is proposed that FGF19 has lipid-raising and lipid-lowering actions mediated through different FGF receptors and target tissues, and the results described here provide a potential mechanism that may explain the inconsistency in the reported effects of FGF 19 on lipid metabolism.
60
Optimization of the heterocyclic core of the quinazolinone-derived CXCR3 antagonists.
An-Rong Li,Michael G. Johnson,Jiwen Liu,Xiaoqi Chen,Xiaohui Du,Jeffrey T. Mihalic,Jeffrey Deignan,Darin J. Gustin,Jason Duquette,Zice Fu,Liusheng Zhu,Andrew P. Marcus,Phillipe Bergeron,Lawrence R. McGee,Jay Danao,Bryan Lemon,Teresa Arazas Carabeo,Tim Sullivan,Ji Ma,Liang Tang,George Tonn,Tassie L. Collins,Julio C. Medina +22 more
TL;DR: A series of six-six and six-five fused heterocyclic CXCR3 antagonists has been synthesized and their activities evaluated in an [(125)I]-IP-10 displacement assay and an ITAC mediated in vitro cell migration assay, leading to the discovery of compounds with increased potency and improved pharmacokinetic properties that could serve as useful tools to study the role of the CX CR3 receptor in vivo.
57
Imidazo-pyrazine derivatives as potent CXCR3 antagonists
Xiaohui Du,Darin J. Gustin,Xiaoqi Chen,Jason Duquette,Lawrence R. McGee,Zhulun Wang,Karen Ebsworth,Kirk Henne,Bryan Lemon,Ji Ma,Shichang Miao,Emmanuel Sabalan,Tim Sullivan,George Tonn,Tassie L. Collins,Julio C. Medina +15 more
TL;DR: Optimization efforts led to the discovery of a series of imidazo-pyrazine derivatives with improved pharmacokinetic properties in addition to increased potency of CXCR3 antagonists with fused hetero-bicyclic cores.
46